Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Daiichi Sankyo Company ( (JP:4568) ) has shared an announcement.
Daiichi Sankyo has released its consolidated financial reference data for the third quarter of fiscal year 2025, providing detailed information on profit or loss, core operating profit adjustments, revenues by global products and business units, and its consolidated financial position and cash flows. The disclosure also covers operational metrics such as employee numbers, capital expenditure, depreciation and amortization, product outlines, quarterly and historical performance data, and a summary of its major innovative pharmaceutical R&D pipeline, offering stakeholders a comprehensive view of the company’s current financial health and longer-term development trajectory.
The most recent analyst rating on (JP:4568) stock is a Hold with a Yen3118.00 price target. To see the full list of analyst forecasts on Daiichi Sankyo Company stock, see the JP:4568 Stock Forecast page.
More about Daiichi Sankyo Company
Daiichi Sankyo Co., Ltd. is a Japan-based global pharmaceutical company listed on the Tokyo Stock Exchange that focuses on innovative prescription medicines. Its core business spans research, development, manufacturing, and commercialization of pharmaceuticals, with an emphasis on oncology and other specialty therapeutics for global markets.
Average Trading Volume: 7,502,961
Technical Sentiment Signal: Sell
Current Market Cap: Yen5674.1B
See more insights into 4568 stock on TipRanks’ Stock Analysis page.